Compare Flagstar Bank NA (FLG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Recursion Pharmaceuticals Inc — how do they compare? Flagstar Bank NA trades at $15.36 (market cap $6.26B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.75B). The key difference: Flagstar Bank NA is far larger — about 3.6× Recursion Pharmaceuticals Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FLG | RXRX | |
|---|---|---|
Market Cap | $6.26B | $1.75B |
Sector | Financials | Health |
52-Week High | $15.28 | $6.79 |
52-Week Low | $10.72 | $2.84 |
Dividend Yield | 0.27% | — |
Enterprise Value | — | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $15.285, up 2.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.05. Recent earnings beat expectations in Q4 2025 and Q1 2026, though the company remains unprofitable on an annual basis with a net income margin of -2.71% in 2026. Positive developments include a proprietary technology transformation and a recent dividend declaration.
The outlook is cautiously optimistic, supported by analyst buy ratings and improving fundamentals, but risks include persistent negative profitability and high interest expenses. Upside is tied to continued execution on the turnaround and future earnings growth.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
